|Other Names||Calcipressin-2, Down syndrome candidate region 1-like 1, Myocyte-enriched calcineurin-interacting protein 2, MCIP2, Regulator of calcineurin 2, Thyroid hormone-responsive protein ZAKI-4, RCAN2, DSCR1L1, ZAKI4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6316a was selected from the Center region of human DSCR1L1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Could play a role during central nervous system development.|
|Tissue Location||Expressed in fibroblasts, heart, brain, liver, and skeletal muscle but not in placenta, lung, kidney and pancreas|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DSCR1L1 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. This protein may play a role during central nervous system development. Expression is detected in fibroblasts, heart, brain, liver, and skeletal muscle but not in placenta, lung, kidney and pancreas. Expression of both transcripts is upregulated by physiologic concentrations of the thyroid hormone triiodothyroxine.
Rothermel, B., et al., J. Biol. Chem. 275(12):8719-8725 (2000).Fuentes, J.J., et al., Hum. Mol. Genet. 9(11):1681-1690 (2000).Strippoli, P., et al., Genomics 64(3):252-263 (2000).Miyazaki, T., et al., J. Biol. Chem. 271(24):14567-14571 (1996).Cao, X., et al., Biochem. J. 367 (PT 2), 459-466 (2002) (): ().
If you have any additional inquiries please email technical services at firstname.lastname@example.org.